# In-vivo Transmission Model in Semi-immune Adults

> **NCT06172686** · PHASE1 · UNKNOWN · sponsor: **Ifakara Health Institute** · enrollment: 24 (estimated)

## Conditions studied

- Controlled Human Malaria Infection
- Induced Blood Stage Malaria Infection
- Malaria Transmission
- Malaria Challenge

## Interventions

- **DRUG:** Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).
- **DRUG:** Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.

## Key facts

- **NCT ID:** NCT06172686
- **Lead sponsor:** Ifakara Health Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-09
- **Primary completion:** 2024-02-13
- **Final completion:** 2024-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172686, "In-vivo Transmission Model in Semi-immune Adults". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06172686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*